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RÉSUMÉ 
Les bactéries magnétotactiques (BMT) peuvent être utilisées pour des applications biomédicales 
telles que la délivrance de médicaments. Les BMT sont encapsulées dans des transporteurs 
comme les liposomes, afin d’être capable de contrôler la navigation des BMT à travers les 
vaisseaux sanguins et de protéger les cellules normales des effets nuisibles des médicaments 
anticancéreux attachés aux BMT.           
Dans notre étude, nous avons étudiés les caractéristiques des liposomes composés de DMPC par 
la technique d’hydratation de couche lipidique afin d’évaluer leurs disponibilité à être manipulé 
en tant que transporteur de BMT.  Les résultats ont montré que la technique d’hydratation des 
couches de lipides présente une importante reproductibilité des liposomes. Environ 1,500,000  
liposomes ayant un diamètre de 8 à 23 μm pour chaque ml de solution de liposome ont été 
préparés par cette technique. Les liposomes préparés ont encapsulés 14,1% de la quantité ciblée 
de BMT.  
Les filtres de polycarbonate ont séparé 90,63% de BMT non encapsulées qui sont restées dans 
l'échantillon à la fin du processus d'encapsulation. En outre, les filtres de polycarbonate n'ont pas 
montré d'effets négatifs reconnaissables sur l'intégrité des liposomes, du fait que 79.6% des 
liposomes qui ont subi le procédé de séparation par des filtres de polycarbonate pour l'isolement 
de BMT non encapsulées, ont été maintenus intacts après que la séparation des BMT non 
encapsulées a eu lieu. 
La faible fréquence des ultrasons, 3W/cm3, pendant 3 minutes a libéré 95% des liposomes 
composés de DMPC. Selon nos résultats, la température corporel et le pH du corps n’ont pas pu 
causer la libération de liposomes composés de DMPC pendant 30 minutes d’exposition.  
Nous avons conclu le fait que la technique d’hydratation des couches de lipides est fortement 
reproductible. Cette technique est capable de produire des liposomes ayant un grand diamètre 
pouvant piéger une quantité suffisante de particules ayant un diamètre de l’ordre des 
micromètres. De plus, les filtres de polycarbonate sont capables de séparer les BMT non 
encapsulés  des échantillons de liposomes sans affecter l’intégrité des liposomes. La faible 
fréquence de l’ultrason a permis d’obtenir un fort pourcentage de liposomes alors que la 
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température corporel et le pH n’ont pas été capable de causer la libération de liposomes 
composés de DMPC pendant les 30 premières minutes d’injection dans le corps.  
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ABSTRACT 
Magnetotactic bacteria (MTB) could be used in biomedical applications such as drug delivery. 
To be able to control the navigation of MTB through blood vessels and protect the normal cells 
from the harmful effects of anticancer medications attached to MTB, we have to encapsulate 
MTB inside carriers such as liposomes.  
In our study, we studied the characteristics of liposomes composed of DMPC by lipid film 
hydration technique to evaluate their availability to be manipulated as MTB carriers. The results 
showed that the lipid film hydration technique manifests high liposomes reproducibility. Around 
1,500,000 liposomes with diameters between 8-23 μm in every 1ml of liposomes solution are 
prepared using this technique. The prepared liposomes encapsulated 14.1% of the targeted 
quantity of MTB to be entrapped inside liposomes. 
The polycarbonate filters segregated 90.63% of non-encapsulated MTB that remained in the 
sample after the encapsulation process is achieved. In addition, the polycarbonate filters did not 
show recognizable negative effects on the liposomes’ integrity since 79.6% of the liposomes 
underwent the separation process by polycarbonate filters for the isolation of non-encapsulated 
MTB are kept intact after the separation of non-encapsulated MTB had taken place. 
The low frequency ultrasound 3W/cm3 for 3 minutes released 95% of the liposomes composed of 
DMPC. According to our results, the both body temperature and body pH could not cause the 
release of liposomes composed of DMPC during 30 minutes of exposure.  
We concluded that the lipid film hydration technique is high reproducible technique. This 
technique is able to produce liposomes with big diameters that could entrap sufficient amount of 
particles in micrometers in their diameters. In addition, the polycarbonate filters are able to 
separate the non-encapsulated MTB from liposomes sample without affecting the integrity of 
liposomes. The low frequency ultrasound releases a high percentage of liposomes while both 
body temperature and body pH are not able to release liposomes during the first 30 minutes of 
their injection into the human body.  
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INTRODUCTION 
According to Canadian statistics, cancer is the first cause of death in Canada. Cancer is 
responsible for 29% of the total number of deaths in Canada [1]. In 2013 approximately 39400 
men and 36100 women died in Canada from different types of cancer [2].  
Conventional ways for administrating chemotherapies lack specificity because chemotherapeutic 
agents kill both normal and cancerous cells that frequently lead to toxicity and complications that 
could be lethal [3]. 
Professor Sylvain Martel invented a new technique for the targeted administration of therapeutic 
agents based on the exploitation of a specific kind of bacteria called magnetotactic bacteria 
(MTB) strain MC-1 to be used as a carrier for chemotherapeutic agents [4]. 
MTB MC-1 is a specific strain of MTB that are characterized by their spherical shape. Each 
MTB MC-1 bacterium measures 2 μm in diameter and has two flagella bundles providing a 
thrust force exceeding 4 picoNewtons (pN). These flagella allow the MTB to swim in water at 
room temperature at speeds exceeding 200 μm/s [5]. 
 
Each MTB has a chain of nanoparticles called magnetosomes. These magnetosomes can be 
manipulated for controlling swimming speeds and direction of MTB by applying magnetic fields 
to them. In addition, magnetosomes could also be exploited to track the MTB inside human 
blood vessels because magnetosomes cause a local distortion of the magnetic field inside the 
bore of a clinical MRI system [4]. 
 
Anticancer medications can be attached to the MTB by antibodies. Therefore, we can use the 
MTB as a carrier to transport anticancer medications to tumor lesions [4]. To be able to control 
the navigation of the MTB through the blood vessels and protect normal cells from the harmful 
effects of anticancer medications attached to the MTB, we have to encapsulate the MTB inside 
carriers like liposomes. 
 
To be able to manipulate liposomes to encapsulate MTB attached to anticancer medications, we 
have to study the characteristics of liposomes aimed to be manipulated for the targeted delivery. 
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In the first chapter, we explain the cancer and medications available for it, the MTB and how can 
be used as nanorobots inside the human body, and liposomes and their role as medications 
carriers. We explain the methods that we manipulate to encapsulate the MTB in liposomes, to 
separate non-encapsulated MTB from liposomes sample, and to release liposomes composed of 
DMPC in the second chapter. We present our results in the third chapter and discuss them in the 
fourth chapter. 
 
The general objective of this work: 
The general objective of this research is to study the characteristics of liposomes composed of 
DMPC by lipid film hydration technique. We will evaluate the reproducibility of the lipid film 
hydration technique and assess the size of produced liposomes. We aim to evaluate the 
encapsulation efficacy for liposomes composed of DMPC produced by the lipid film hydration 
method for bacteria in micrometer in their sizes. In addition, the release efficacy of release 
techniques on liposomes composed of DMPC will be studied as well. 
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CHAPTER 1    LITERATURE REVIEW 
1.1 Cancer  
Cancer is a disease in which abnormal cells grow uncontrollably due to the loss of control of cell 
division by normal mechanisms of cell division. In this disease, normal cells convert to 
cancerous cells that divide without control resulting in solid masses called tumours [6]. There are 
many types of cancer influences on the most organs in the human body [7]. 
Tumours are classified according to their degree of aggressive growth to benign and malignant 
tumours. Benign tumours usually exist in certain tissues without invading the adjacent tissues 
while malignant tumours have the ability to invade other tissues in the body through a process 
called metastasis [8]. 
Metastasis is a multistep process during which cancerous cells spread from the initial tumour to 
distant tissues. This complex process starts by the separation of cancerous cells from the initial 
tumour and the invasion of nearby tissues until the cancerous cells reach the blood or lymphatic 
circulations. By immigration through the blood and lymphatic circulations, cancerous cells reach 
distant tissues in the body where they stop and colonize these tissues. When cancerous cells 
invade new tissues, they proliferate and induce a process called angiogenesis [9]. 
Angiogenesis is the process that involves the formation new blood vessels from the normal 
existing blood vessels by the activation of the migration of endothelial cells of pre-existing blood 
vessels to form new blood vessels. The angiogenesis process is essential for the growth of 
tumours because it enhances the growth and spreading of tumours by providing cancerous tissues 
with oxygen and nutrients and removing waste products [10, 11].   
According to the International Agency for Research on Cancer (IARC), the estimated number of 
deaths related to cancer in the world in 2012 was around 8.2 million accompanied with 14.1 
million new cancer cases. These numbers are higher than the number estimated in 2008 with 
12.7 million new cases and 7.6 million death cases. Lung cancer, breast cancer, and colorectum 
are the most commonly diagnosed cancers worldwide making up 13.0%, 11.9%, and 9.7% 
respectively of the total percentage of cancer cases while lung, liver, and stomach cancer are the 
most common causes of death from cancer making up 19.4%, 9.1%, and 8.8% of the total 
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number of deaths respectively worldwide. Estimations predict that there will be 19.3 million new 
cancer cases per year by 2025 because of increasing number of people and ageing populations in 
the world. According to the IARC, in 2012 around 64.9% of the total cancer cases and 56.8% of 
the total number of cancer related deaths took place in less developed countries. Incidences of 
cancer increased in all countries with more cases estimated in the more developed countries, but 
death cases are higher in less developed countries because they lack the ability to detect cancer 
early and they also have less treatments available to them [7]. 
There are many risk factors that increase the probability of incidences of cancer. In general, any 
type of cancer is associated with risk factors that promote the development of the specific type of 
cancer. For instance, smoking and inhalation of tobacco smoke, the consumption of saturated 
fats, red meat, dairy products and alcohol enhance the development of lung cancer [12]. The risk 
of devolving breast cancers decreases in women with histories of breast-feeding while it 
increases in overweight women, women who consume alcohol and women who smoke [13]. Oral 
contraceptives, elevated iron storage in the body, obesity, tobacco smoking, and alcohol 
consumption are the most common risk factors of liver cancer [14]. 
There are a lot of symptoms that are associated with cancer diagnosed people, such as fatigue, 
pain, lack of energy, weakness, loss of appetite, weight loss, dry mouth, anxiety, early satiety, 
sore mouth, insomnia, depressed mood, taste changes, confusion, dysphagia, nausea and 
vomiting, constipation, bleeding, irritability, and diarrhea [15]. 
1.1.1 Radiation therapy 
Around 50% of cancer patients are treated with radiotherapy with the aim of preventing 
cancerous cells from multiplying by inhibiting the cell division of cancerous cells. This type of 
treatment is either used alone or with other cancer medications such as chemotherapy or surgery 
depending on the medical purpose it is used for. For instance, radiotherapy is utilized before 
surgery to shrink the tumour size and it is used after surgery to destroy microscopic cancerous 
cells that are not removed by surgery [16, 17]. Radiation is a physical treatment that depends on 
using x-rays and gamma rays to kill cancerous cells. The radiation used in radiotherapy is called 
ionizing radiation because it composes ions. When radiation passes through cancerous tissues, it 
deposits energy in the cancerous cells of the tissues and the deposited energy kills cancerous 
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cells or causes genetic modifications in the cancerous cells leading to their death [17]. Generally, 
radiation is directed towards cancerous cells using two approaches. One of the procedures of 
delivery is called external beam radiation, which is based on directing high-energy rays such as 
photons, protons or particle radiation from outside the body to the place of cancerous cells inside 
the body. Another procedure called internal radiation is when radiation is delivered from inside 
the body by radioactive sources sealed in catheters [17]. The main drawback of using 
radiotherapy to treat cancers is the exposure of the normal cells to radiation during the exposing 
of cancerous tissues to radiation therapy. The symptoms of destroying normal cells by 
radiotherapy will appear during the period of treatment or later. For instance, symptoms such as 
fibrosis appear six weeks after irradiation of a lung. These symptoms appear as a result of cell 
death in irradiated tissue [17, 18]. Acute damage due to radiation also occurs in tissues that are 
characterized by rapid proliferating cells such as in the epithelial surfaces of the skin or the 
alimentary tract [18]. In addition, radiotherapy does not kill cancer cells right away because 
radiation takes time to kill cancerous cells. It takes hours, days or weeks of treatment before 
cancerous cells start to die [17]. People treated with radiotherapy are suspected to develop 
erythema in the skin and experience an elevation in intracranial pressure in the central nervous 
system [18]. Determining the dose of radiation needed is also another problem related with 
utilizing radiation because there are only a few studies that have been developed to detect the 
maximum tolerated dose of radiation at any specific place in the body. Some damage in some 
tissues might be acceptable especially when the benefits earned are greater than the damage 
caused, while the damage is not allowed to happen especially in vital organs such as the central 
nervous system [18]. Using this type of treatment for cancer patients achieves different degrees 
of efficacy. For example, the probability of staying alive after radiotherapy for a patient with 
some cancerous cells such as an early stage of larynx cancer and a non-small-cell lung cancer is 
high whereas for some cancerous cells such as sarcomas and advanced non-small-cell lung 
cancer the likelihood of liveability is low. In addition, many patients will experience recurring 
disease after radiotherapy [16]. Some latest effects due to exposure to radiation appear many 
years after treatment, such as fibrosis, necrosis, atrophy, and vascular damage [18]. 
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1.1.2 Surgery 
Surgery is one of the most commonly used techniques to eradicate solid tumours, but many 
complications are associated with using this technique for cancer treatment, such as pain, tissue 
damage, and inflammation. Moreover, recurrence of cancer and metastasis happens sometimes 
after the removal the initial cancer by surgery [19]. In addition to the general complications 
related with cancer surgery, many complications are related to surgical eradication of specific 
types of cancers. For example, there are many drawbacks associated with breast cancer surgery, 
such as wound infections, seromas, and hematomas that happen in around 30% of patients. 
Theses complications require prolonged hospitalization of patients. Mondor’s disease, 
thrombosis of the thoracoepigastric vein, pneumothorax, and brachial plexopathy occur in some 
patients who undergo surgical breast procedures [20]. Many medical problems arise as a result of 
the surgical treatment of pancreatic cancer, such as cardiac problems, cerebrovascular accidents, 
respiratory distress, renal dysfunction, pneumonia, pulmonary embolism, hepatic and metabolic 
dysfunction [21]. 
1.1.3 Chemotherapy 
A lot of medications are utilized as chemotherapies, such as antimetabolites, alkylating agents, 
antibiotics, plant alkaloids, hormones, and biologic response modifiers. This type of cancer 
treatment is based on using therapeutic agents that target the killing of rapidly dividing cells 
through different mechanisms of action. For instance, antimetabolites overlap with the 
production of the nucleic acids of rapidly dividing cancerous cells by different mechanisms. One 
of these mechanisms is the prevention production of the deoxyribonucleoside triphosphates, 
which are precursors for DNA synthesis [22]. Since chemotherapies kill rapidly dividing cells, 
these medications do not differentiate between normal and cancerous rapidly dividing cells. 
Therefore, using these medications for killing cancerous tissues is usually associated with 
toxicity [3]. Nausea and vomiting are the most common side effects of anticancer medications 
that could lead to other complications, such as dehydration and electrolytes imbalance that 
require hospitalization for a period of time. Many patients refuse to continue their treatment 
courses because of these complications [23]. Alopecia (losing hair) is a common side effect of 
chemotherapies that has negative effects on the psychology of patients. Many patients avoid 
participation in social activities and going to work because of their appearance [24]. Hepatic 
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toxicity is one of the dangerous drawbacks of chemotherapeutic agents. These agents could cause 
mild toxicity via the elevation of liver enzymes or severe toxicity via composing fibrosis or 
cirrhosis [25]. Cardiotoxicity happen as a result of using some chemotherapeutic agents such as 
doxorubicin and daunorubicin. The negative effects of using these medications include sinus 
tachycardia, premature ventricular and atrial contractions [25]. In addition to previously 
mentioned side effects of chemotherapies, there are many neurological side effects as a result of 
using these medications such as confusion, disorientation, cerebellar ataxia, cranial nerve palsy, 
and autonomic neuropathy. Moreover, chemotherapeutic agents cause genitourinary toxicity, 
pulmonary toxicity, chronic skin changes, mucositis, and other complications [25]. 
1.2 Magnetotactic bacteria (MTB) 
MTB are gram-negative motile bacteria that are able to migrate along geomagnetic ﬁeld lines 
because they have small intracellular mineral organelles bounded to their membranes called 
magnetosomes [26].  
Magnetosomes are nanometre-sized particles called magnetite of iron oxide (Fe3O4) or greigite 
of iron sulﬁde (Fe3S4) arranged in 1, 2 or more chains. These mineral particles are surrounded by 
a bilayer membrane of phospholipids. The magnetosomes that are in the middle of a chain are 
bigger than the magnetosomes that are present at the end of a chain since the magnetosomes that 
are at the end of a chain are the newly synthesized ones. These magnetosomes have many 
shapes. For example, some of them have a bullet shape while others take on a cubooctahedral 
shape and some of them are rectangular [26, 27].  
 
Figure 1-1: Images of shapes and arrangements of magnetosomes [28]. 
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Magnetic interactions between the magnetosomes in a chain create their magnetic dipole 
moments. Therefore, the total magnetic dipole moment of any cell is the sum of the overall 
dipole moments of the magnetosomes. This magnetic dipole moment causes the cell to arrange 
itself along geomagnetic field lines while it swims in a phenomenon called magnetotaxis [28]. 
The direction of movement of MTB is controlled by chemotaxis, aerotaxis, and magnetotaxis, 
but when the MTB are exposed to a significant magnetic field the magnetotaxis overcomes the 
influence of chemotaxis and aerotaxis and subsequently the MTB are fully controlled by the 
effect of the magnetotaxis [4].  
MTB exist in many morphological shapes, such as bacillus, vibrios, spirilla, and cocci. Some 
MTB strains have the ability to live in fresh water whereas other MTB live in marine water. 
Specific species of MTB produce iron oxide while others produce iron sulﬁde and some species 
produce both iron oxide and iron sulphide. Iron oxide-producing MTB exist just in the fresh 
water while MTB producing both iron oxide and iron sulphide are found in marine water and 
lakes [27].   
MTB are classified according to their response to magnetic fields. Axial MTB have the ability to 
migrate to both magnetic poles with continuous switching in their migration direction along 
magnetic field lines. Contrarily, polar MTB migrate in the direction of one pole. For instance, 
polar MTB that migrate in direction of the North Pole exist in the Northern Hemisphere and are 
called north-seeking MTB while polar MTB that migrate in the direction of the South Pole are 
exist in the Southern Hemisphere and are called south-seeking MTB [29]. 
Although there are a lot of strains of MTB in marine and fresh water, there are specific strains 
that are isolated in pure cultures, such as Magnetospirillumgryphiswaldense MSR-1, 
Magnetospirillummagneticum AMB-1, Magnetospirillummagneticum MGT-1, Magnetovibrio 
MV-1, Magnetococcus sp. MC-1, Marine Magnetic spirillum QH-2, Magne- tospirillumsp.WM 
1 and Magnetospirillummagnetotacticum MS-1 [27]. 
1.2.1 Choosing a strain of MTB to be manipulated as a medication carrier 
As we mentioned earlier, few strains of MTB can be isolated and cultured. The fundamental 
criteria for selecting a species of MTB to be applied as microrobots inside the human body are 
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the swimming speed of the MTB, the size of the MTB, and the ability to control the movement 
of the MTB [4].  
Strains of MTB have different swimming speeds. For instance, MTB MV-4 have a swimming 
speed around 30-80 µm s-1. Magnetotactic spirilla have a swimming speed of less than            
100 µm s-1 while Magnetococcus sp. MC-1 have swimming speeds around 200-300 µm s-1. The 
MV-4 strain of MTB is the smallest in size. Each MV-4 bacterium is 0.5 µm in length while the 
MC-1 strain is bigger in size since MTB MC-1 are 2 µm in size. Both MV-4 and MC-1 are polar 
MTB because both of them only have 2 flagellum on 1 side of the MTB. This feature makes 
them swim in only 1 direction through the magnetic field. Therefore, their movement is easier to 
control than the axial MTB who have flagella on both sides of the cells such as the 
Magnetospirillum gryphiswaldense MTB. The swimming direction of the axial MTB is 
unpredictable since this strain of MTB migrates in the both directions of the magnetic field with 
approximately the same number of MTB migrating in each direction. From the previous data, we 
can conclude that MC-1 MTB is the best strain of MTB to be exploited as microrobots for 
transport medications inside the human body [4, 29, 30]. 
1.2.2 MTB MC-1 
MC-1 MTB is a specific stain of MTB which has a spherical shape with a diameter of around     
2 µm. Each bacterium has 2 flagella on 1 side of the cell providing it with a thrust force of 
around 4 pN. The thrust force provided by bundles of flagella enables every cell to swim in water 
at room temperature and without load at speeds around 200-300 µm s-1[29]. 
 
Figure 1-2: Image showing MC-1 bacterium cell morphology [4]. 
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The MC-1 strain grows in a chemoheterolithotrophic liquid medium under microaerobic 
conditions. Iron-enrichment of the medium is achieved using 50 µM of ferrous sulfate 
heptahydrate  FeSO 4.7H2O [31]. 
The MC-1 strain of MTB has magnetosomes that are responsible for magnetotaxis that has an 
effect on determining the movement direction of the MTB, but the movement direction of MC-1 
is also affected by chemotaxis and aerotaxis. Magnetotaxis is the most convenient way to guide 
MC-1 inside the maze of blood vessels in the human body. By applying a magnetic field higher 
than the magnetic field of the earth (0.5 Gauss), the movement direction of the MC-1 will be 
fully influenced by magnetotaxis [29]. 
Tracking movement of MTB inside the human body is done using the Resonance Imaging 
System (MRI). The magnetosomes of the MTB are manipulated to track the movement of MTB 
using the MRI system because the magnetosomes cause disturbances in the local magnetic field 
that have an affect on the spin-lattice T1 and spin-spin T2 relaxation times during MRI [32].   
In vitro studies are done to evaluate the ability of MC-1 to penetrate through solid tumours. The 
results collected from studying the penetration of MC-1 through 3D models composed of 
multicellular tumour spheroids (MCTS) simulating the structure of solid tumours show that   
MC-1 are able to penetrate inside the 3D multicellular tumour spheroids [31,33].  
MTB MC-1 are loaded with particles with sizes of around 150 nm. The MC-1 are attached to 
these particles using antibodies. The size of these particles is sufficient to provide the tumour 
lesions with enough concentration of anticancer medication without affecting the swimming 
speed of the MTB [4].  
1.3 Liposomes 
Liposomes are spherical vesicles composed of 1 or more lipid bilayers enclosing aqueous 
compartments inside them [34, 35]. They have the ability to encapsulate particles inside both the 
aqueous solution and in the lipid bilayer. For instance, liposomes encapsulate the lipophilic drugs 
in the lipid bilayer and encapsulate the hydrophilic drugs in the aqueous compartment [34].  
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Figure 1-3: Sketch explaining the general structure of liposomes [36]. 
 
Liposomes can be classified according their sizes and the number of bilayers as in the following 
[37]: 
1. Small unilamellar vesicles (SUV) are between 20-100 nm. 
2. Large unilamellar vesicles (LUV) are more than 100 nm. 
3. Giant unilamellar vesicles (GUV) are bigger than 1000 nm in size. 
4. Oligolamellar vesicles (OLV) are 100-500 nm in size. 
5. Multilamellar vesicles (MLV) are bigger than 500 nm in size but are composed of many 
layers. 
 
1.3.1 Advantages of using liposomes as medication carriers [38] 
1. Liposomes are composed of phospholipids that do not cause any toxicity inside the human   
body.  
2.  They are biodegradable and biocompatible. 
3.  Liposomes are usually used for the targeted delivery of medications because they allow us to 
deliver medications to desired places. 
4.  Liposomes enable us to achieve higher therapeutic efficacy.  
5. Encapsulation of medications inside liposomes decreases the toxicity of medication by 
increasing the concentration of the drug in the targeted area and decreasing side effects of 
drugs on normal cells.   
6.  Liposomes keep encapsulated particles stable until they reach the place of release.  
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1.3.2 Disadvantages of using liposomes as medication carriers [39] 
1. Liposomes are expensive to produce because of the high cost of artificially synthesized 
phospholipids.  
2. Liposomes are unstable. 
1.3.3 Structure of liposomes 
In general, liposomes are composed of phospholipids and cholesterol [40]. Phospholipids have a 
general structure composed of glycerol, fatty acids, and organic alcohol. Glycerol is considered 
to be the backbone of phospholipids and is composed of 3 carbon atoms. 2 of these carbon atoms 
are connected to 2 chains of fatty acids from 1 side and the 3rd carbon atom is attached to organic 
alcohol that is connected to a phosphate group from another side. The fatty acid region of 
phospholipids is called the non-polar region or the hydrophobic region. The alcohol group that is 
attached to the phosphate group forms hydrogen bonds with water. This region of phospholipids 
is called the polar region or the hydrophilic region. Because the phospholipids contain both 
hydrophilic and hydrophobic regions they are called amphipathic molecules [41].   
 
Figure 1-4: Sketch representing the general structure of phospholipids [41]. 
 
When a phospholipid is exposed to water, the polar alcohol molecules (heads) arrange against 
the non-polar fatty acids (tails). As a result, the polar regions face the water while the non-polar 
regions face each other away from the water, forming a lipid bilayer [41].  
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Figure 1-5: Sketch of the arrangement of the lipid bilayer [41]. 
 
Each phospholipid has its own transition temperature. The transition temperature (Tc) of the 
phospholipids is the temperature that is needed to change the lipid from the gel phase to the 
liquid phase. The main factors that determine if a phospholipid has a low or high transition 
temperature are the hydrocarbon length of the fatty acids, saturation, and the head group species 
[42]. 
Table 1-1: Transition temperature of the main synthetic phospholipids [42] 
Name of the phospholipid Transition temperature 
DLPC - 1°C 
DMPC 23°C 
DPPC 41°C 
DSPC 55°C 
DOPC - 20°C 
DMPE 50°C 
DPPE 63°C 
DOPE - 16°C 
 
Cholesterol is a steroid composed of 4 fused rings with one hydroxyl group at carbon atom 
number 3, and a double bond between carbon atoms 5 and 6, and an iso-octyl hydrocarbon side 
chain at carbon atom 17 [43]. 
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Figure 1-6: The chemical structure of cholesterol [43]. 
 
Liposomes are prepared of just phospholipids or phospholipids and cholesterol. Corporation of 
cholesterol in liposomes changes physic-chemical characters of liposomes [44]. Cholesterol has 
the ability to increase the transition temperature of liposomes and enhances the rigidity of the 
liposomes. In addition, it increases the stability and decreases the deformity of liposomes. As a 
result, it prolongs the life of liposomes inside the blood vessels. Cholesterol performs these 
actions because it increases the packing density of the phospholipids fatty acids chains by 
reducing the rate of motion of the hydrocarbon chains of phospholipids fatty acids [44].  
 
1.3.4 Techniques used for preparation of liposomes 
 
1.3.4.1 The electroformation technique 
The electroformation technique was introduced by Angelova and Dimitrove, who prepared GUV 
with diameters exceeding 10 µm. In this technique, a phospholipid solution in chloroform is 
spread at a constant speed with a micropipette tip on the electrode substrates of indium tin oxide 
or silicon. The electrode substrate is separated from the ITO counter-electrode using a 1mm 
silicon rubber spacer. After the phospholipid film is dried under a vacuum a swelling solution is 
introduced between the 2 electrodes. Electroformation is performed using a sinusoidal AC field 
(10 Hz) for at least 90 minutes. After using the electricity, the liposomes are produced with 
relatively large sizes (10 -100µm) [45-47]. 
 
1.3.4.2 Microfluidic devices 
 
Microfluidic devices are widely used for the preparation of liposomes. Microfluidic devices that 
are used to produce liposomes are fabricated out of many substances such as silicon and 
polymethyl methacrylate. Many research groups prepare liposomes by injecting lipids dissolved 
in an organic solvent such as ethanol or chloroform as a lipid phase from the central inlet by 
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injection pump and injection buffer saline or water containing particles to be entrapped inside 
liposomes from 2 side inlets as a water phase in microfluidic devices by injection pumps. 
Liposomes are composed when the oil phase intersects with the water phase and collected at the 
outlet of the microfluidic device [48, 49]. 
 
1.3.4.3 The lipid film hydration technique 
One of the most frequently used techniques to produce liposomes is lipid film hydration. In this 
method, the phospholipids dissolve in an organic solvent and then the solvent evaporates in a 
rotary evaporator under a low vacuum until the lipid film is composed on the conical flask sides. 
Once the lipid film is totally dry, the phosphate buffer saline is added and rotated for 30 minutes 
inside the water bath above the transition temperature of the used phospholipid and 30 minutes 
outside the water path to get liposomes. This method produces liposomes with large diameters 
[50-52]. 
 
1.3.4.4 Sonication 
Sonication is a resizing process to prepare SUV vesicles with diameters between 15-50 nm from 
the MLV. There are many instruments used to get SUV from MLV such as bath and probe tip 
sonicators. The SUV are prepared from MLV by placing a glass vial containing the MLV in a 
bath sonicator or immersing the tip of the sonicator in a glass vial and sonicating it for 10 
minutes. This technique produces small liposomes that have diameters less than the diameter of 
MTB [53, 54]. 
 
1.3.4.5 Extrusion 
Extrusion is another method for resizing the liposomes. We can get SUV from MLV using this 
technique. In this method, MLV are extruded through polycarbonate membranes with definite 
pore sizes to produce SUV. This method is better than the sonication method because it is simple 
and rapid and does not have negative effect on the stability of materials used for the preparation 
of liposomes, but the MTB is very large comparing to liposomes prepared by this procedure [55, 
56].   
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1.3.4.6 The ether injection method 
The ether injection method is a method to prepare SUV. This technique includes the  preparation 
of liposomes by slowly injecting of phospholipids dissolved in diethyl ether by infusion pump to 
the aqueous solution of the particles that are targeted to be entrapped inside liposomes at         
55-65°C followed by removing the solvent from the sample using a vacuum to get liposomes. 
This technique yields liposomes with tiny diameters that are smaller in size than the MTB [57, 
58].  
 
1.3.4.7 The ethanol injection method 
 
The ethanol injection method is a method used to prepare liposomes by slowly injecting of a 
phospholipid dissolved in ethanol to buffer solutions that contain the material aimed to be 
entrapped inside liposomes at 55‐65°C with continuous stirring by a magnetic stirrer. The 
solvent is removed from the sample either by heating or stirring. Disadvantage of this technique 
is that the sizes of the liposomes are small compared to the MTB sizes [59-61]. 
 
1.3.4.8 The reverse phase evaporation method 
The reverse phase evaporation method is a method used to prepare LUV around 400 nm in 
diameter that have around 65% encapsulation efficacy. We can prepare liposomes by this method 
using the sonication of phospholipids dissolved in organic solvent and aqueous buffers for          
5 minutes at 25°C to compose inverted micelles. After getting the micelles, organic solvents are 
removed from the sample under low pressure until achieving a viscous gel. To get liposomes, we 
agitate the gel in the vortex. The main drawback of this method is that liposomes prepared by 
this technique are smaller than MTB that are meant to encapsulate them [62, 63]. 
 
1.3.4.9 Freeze drying (lyophilization)      
This method is usually used for the preparation of unilamellar vesicles with sizes of around      
200 nm. In this technique, phospholipids and lyoprotectans such as sucrose or lactose are 
dissolved in a solvent such as chloroform to compose a monophase solution. After that, the 
monophase solution undergoes to sterilization and it is loaded in vials to be freeze dried. The 
freeze drying is performed in a freeze drier by freezing at - 40°C for 8h followed by primary 
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drying at - 40°C for 48h and secondary drying at 25°C for 10h. The pressure is kept constant at 
20 Pascal during the drying. The liposomes are produced by adding water to the lyophilized 
product. The liposomes produced by this technique are very small compared to the sizes of MTB 
that will be entrapped inside them. Therefore, this technique is inappropriate for encapsulating 
the MTB [37, 64]. 
 
1.3.4.10 Detergent dialysis     
This technique is used to prepare unilamellar liposomes between 40–200 nm in their sizes that 
have high encapsulation efficacy. This method is based on the preparation of liposomes from 
micelles. These micelles are composed of solubilizing phospholipids with detergent in the 
desired buffer solution. When the micelles are prepared, the detergent is removed by dialysis to 
get homogeneous unilamellar liposomes. Unfortunately, liposomes produced by detergent 
dialysis are smaller than MTB that are aimed to be encapsulated inside liposomes [37].  
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CHAPTER 2    METHODOLOGIES 
This project is composed of 3 main steps. The first step is the encapsulation of MTB in large 
liposomes. After achieving this step successfully, the non-encapsulated MTB are removed by 
separation techniques to get rid of non-encapsulated MTB for 2 main reasons. The first reason is 
to study the encapsulation efficacy of liposomes prepared by lipid film hydration technique. The 
second reason is to evaluate the efficacy of the release techniques on release of liposomes 
composed of DMPC. When the non-encapsulated MTB are removed, the sample free of non-
encapsulated MTB are released by the known techniques for the release liposomes. 
                     
Figure 2-1: The plan of  work for the studying the characteresics of liposomes composed of 
DMPC by lipid film hydration technique.  
2.1 MTB MC-1 culture and microscope setup 
MTB MC-1 are cultured in chemoheterolithotrophic liquid medium under microaerobic 
conditions. The iron-enrichment of the medium is completed using 50 µM of ferrous sulfate 
heptahydrate  FeSO 4 .7H2O.  
All observations are carried out using a Zeiss Imager Z1 microscope (Carl Zeiss Canada Ltd., 
Toronto, Canada) equipped with a Zeiss Axiocam camera. Observations are completed under 
dark illumination using 2 powers of magnification 20X and 50X.  
 
Step 3
Release of liposomes
Step 2
Separation of non encapsulated MTB
Step1
Encapsulation of MTB in liposomes
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2.2 Experiments setups  
All equipments used in preparation of the liposomes by lipid film hydration are vitreous. The 
conical flask utilized to preparation the liposomes is washed with soap and water followed by 
rinsing it with deionized water many times followed by washing it with acetone (Sigma Aldrich) 
to remove residuals of water from the conical flask. The conical flask is kept in a vacuum hood 
to make sure to get rid of water and acetone from the conical flask. All glass vials used for 
keeping phospholipid are washed with acetone to make sure to remove any water that might be 
present in them. The preparation of the exact concentration of phospholipid is carried out in a 
vacuum hood. A glass syringe is used to withdraw the needed volumes of DMPC and chloroform 
to prepare the exact concentration of phospholipid solution. The phospholipid solution is 
preserved in a tightly closed glass vial covered with parafilm in a cold container until it is used.  
2.3 Keeping materials  
DMPC vials are kept in a refrigerator adjusted at − 18°C. We avoid exposing phospholipids to 
room temperature for long periods during the withdrawal of the required volumes of DMPC from 
the original DMPC volume. Both chloroform and acetone are preserved in a chemical room.  
2.4 Counting the number of MTB and liposomes in 1 ml of a sample 
Each drop of the sample is located on a microscope slide using a pipette. In the case of counting 
the number of MTB in the MTB sample, each drop of MTB is covered with a cover slide 
separated from a microscope slide by 1 cover slide from both sides with a thickness of 150 μm 
whereas in counting the number of liposomes and MTB in the liposome sample, 2 cover slides 
are utilized with an overall thickness equal to 300 μm for the separation. The dimensions of each 
area which are observed under a microscope with a lens of 50X is 180 μm (the length) × 134 μm 
(the width) while the dimensions of the area which is observed under the microscope with a lens 
of 20X is 440 μm  × 330 μm. To calculate the number of liposomes and MTB in 1ml of 
liposomes sample, we calculate the number of liposomes and MTB in 8 different specific sizes 
each of which has dimensions of 180 μm (the length) ×134 μm (the width) × 300 μm (the depth 
of the drop). After we calculate the number of liposomes and MTB in this specific size, we 
calculate the number of liposomes and MTB in each 1ml of the liposomes solution. The same 
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steps are done to count the number of MTB in the MTB sample except by multiplying             
180 μm   × 134 μm or 440 μm × 330 μm in 150 μm instead of multiplying them by 300 μm. 
Every experiment has been repeated 3 times and in every experiment, 8 different readings have 
been recorded. 
2.5 Encapsulation of MTB in liposomes using the lipid film hydration technique 
Materials and instruments 
1,2-ditetradecanoyl-sn-glycero-3-phosphocholine (DMPC) (Avanti polar lipids, Alabaster, 
Alabama, USA), Chloroform (Sigma-Aldrich Canada Co. Oakville, Ontario, Canada), Acetone 
(Sigma-Aldrich Canada Co. Oakville, Ontario, Canada), glass pipette, glass vials, glass syringe, 
MTB, rotary evaporator (BUCHI Switzerland ,Flawil, Switzerland), vacuum source, parafilm 
(Parafilm M Barrier Film, West Chester, PA, USA). 
Procedure 
6.6 mM of DMPC in chloroform is evaporated under a low vacuum in a rotary evaporator 
equipped with a water bath adjusted at 26°C with a rotation speed of 220 rpm for 45 minutes. 
After we get a thin lipid film on the corners of the conical flask, we let the thin lipid film dry 
more by extra evaporation for an additional 45 minutes under a low vacuum to make sure to 
evaporate the residuals of chloroform from the lipid film. When the thin lipid film has dried 
completely, 1.5 ml of MTB in their media with concentration of 5.79×106  per 1 ml are added to 
the lipid film in the conical flask and the conical flask is rotated with a speed of 220 rpm inside 
the water path adjusted at 26°C for 45 minutes to transfer the DMPC from the gel phase to the 
liquid phase. Then the conical flask rotates outside the water path for 45 minutes to transfer the 
DMPC to liposomes that entrap the MTB inside them.  
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Figure 2-2: Sketch explaining the encapsulation of MTB in liposomes using the lipid film 
hydration technique. 
2.6 Preparation 6.6 mM DMPC in solvent  
Molecular weight of DMPC = 677.933 
1M of DMPC solution composed of 677.933 gram in 1000 ml of solvent 
1ml 1M contain 0.6779 gram of DMPC  
0.6779 in 1ml of DMPC                   1000 m M 
X in 1ml of DMPC                                                   6.6 m M 
X = 0.6779 ×6.6 ÷ 1000 
X = 0. 004474 gm in 1ml solvent 
4.47 mg / ml of solvent 
The concentration of DMPC is 25 mg in 1 ml of chloroform  
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25mg  1000 μl of chloroform 
4.47                                             X 
X = 4.47 × 1000 ÷25 
X  = 178.8 μl 
By adding 178.8 μl of DMPC to 821 μl of chloroform, we prepare 1 ml phospholipid solution of 
6.6 m M in chloroform. 
2.7 Separation of non-encapsulated MTB from liposomes by polycarbonate filters 
Equipments and materials 
1,2-ditetradecanoyl-sn-glycero-3-phosphocholine (DMPC) (Avanti polar lipids, Alabaster, 
Alabama, USA), chloroform (Sigma-Aldrich Canada Co. Oakville, Ontario, Canada), acetone 
(Sigma-Aldrich Canada Co. Oakville, Ontario, Canada), glass pipette, glass vials, glass syringe, 
MTB, Rotary evaporator (BUCHI Switzerland, Flawil, Switzerland), vacuum source, Parafilm 
(Parafilm M Barrier Film, West Chester, PA, USA), deionized water, PBS (Sigma-Aldrich 
Canada Co. Oakville, Ontario, Canada), polycarbonate filters with pores of 5 μm (Sterlitech 
Corporation. Kent, WA, USA), Zeiss Imager Z1 microscope (Carl Zeiss Canada Ltd., Toronto, 
Canada). 
Procedure 
The segregation procedure is been done by passing 1.5 ml of deionized water through the 
polycarbonate filter of 5 μm pores followed by passing 1.5 ml of the liposomes solution through 
the polycarbonate filter while continually washing the liposomes solution with PBS to make sure 
to separate most of the non-encapsulated MTB from the liposomes solution. The liposomes that 
remain on the top of the filter are collected and suspended in PBS to make a volume of 1.5 ml. 
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Figure 2-3: Sketch explaining the separation of non-encapsulated MTB from the sample by 
polycarbonate filters. 
2.8 Release of liposomes 
There are many techniques that could be manipulated for the releasing of liposomes, such as 
LFUS, temperature, and pH. The LFUS has the advantage over the other 2 techniques for the 
releasing of liposomes because it is recognized as a controlled way for the release of liposomes 
while the temperature and pH methods are uncontrolled ways for the release of liposomes.  
2.8.1 Release of liposomes by low frequency ultrasound (20 kHz) 
Materials and equipments 
1,2-ditetradecanoyl-sn-glycero-3-phosphocholine (DMPC) (Avanti polar lipids, Alabaster, 
Alabama, USA), chloroform (Sigma-Aldrich Canada Co. Oakville, Ontario, Canada), acetone 
(Sigma-Aldrich Canada Co. Oakville, Ontario, Canada), glass pipette, glass vials, glass syringe, 
MTB, rotary evaporator (BUCHI Switzerland ,Flawil, Switzerland), vacuum source, parafilm 
(Parafilm M Barrier Film, West Chester, PA, USA), deionized water, PBS (Sigma-Aldrich 
Canada Co. Oakville, Ontario, Canada), polycarbonante filter with 5µm pores (Sterlitech 
Corporation. Kent, WA, USA), Zeiss Imager Z1 microscope (Carl Zeiss Canada Ltd., Toronto, 
Canada), ice path, ultrasonic processor (QSONICA, Newtown, CT, USA). 
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Procedure 
After the preparation of liposomes and the separating of the non-encapsulated MTB, 1.5 ml of 
the liposomes solution is added to a glass vial situated in an ice bath to prevent release of 
liposomes by temperature generated during the sonication process. The release of liposomes is 
achieved by the immersion of the sonication probe in the liposomes solution vial and applying 
LFUS of 3W/cm3 for 3 minutes. The amount of liposomes and MTB is counted before and after 
the sonication process and the efficacy of the low frequency ultrasound to release of liposomes is 
studied. 
2.8.2 Release of liposomes by body temperature and body pH  
Materials and equipments 
1,2-ditetradecanoyl-sn-glycero-3-phosphocholine (DMPC) (Avanti polar lipids, Alabaster, 
Alabama, USA), chloroform (Sigma-Aldrich Canada Co. Oakville, Ontario, Canada), acetone 
(Sigma-Aldrich Canada Co. Oakville, Ontario, Canada), glass pipette, glass vials, glass syringe, 
MTB, rotary evaporator (BUCHI Switzerland, Flawil, Switzerland), vacuum source, parafilm 
(Parafilm M Barrier Film, West Chester, PA, USA), deionized water, polycarbonate filter with 
pores of 5 μm (Sterlitech Corporation. Kent, WA, USA), Zeiss Imager Z1 microscope (Carl 
Zeiss Canada Ltd., Toronto, Canada), plastic syringes, PBS (Sigma-Aldrich Canada Co. 
Oakville, Ontario, Canada), controlled water bath (BUCHI Switzerland, Flawil, Switzerland). 
Procedure 
After the preparation of liposomes and the separation of the non-encapsulated MTB by the 
polycarbonate filters, the liposomes are suspended in 1.5 ml PBS and the liposomes solution is 
poured into 6 different plastic vials. These vials incubate in water bath controlled at 37°C for 
different time intervals and the release of liposomes is studied by counting the number of 
liposomes and MTB in the samples before and after exposure to body temperature and body pH. 
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2.9 Studying the effect of body temperature on liveability of MTB 
Materials and instruments 
MTB, plastic vials, pipette, controlled water path, Zeiss Imager Z1 microscope (Carl Zeiss 
Canada Ltd., Toronto, Canada). 
Procedure 
We study the effect of the body temperature 37°C on the liveability of MTB by incubating 6 
different vials each filled with 250 μl of MTB inside the water path adjusted at 37°C. The MTB 
withdraw for different time intervals and are investigated under the microscope to study their 
liveability. 
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 CHAPTER 3   RESULTS 
3.1. Encapsulation of MTB in liposomes 
3.1.1 The number of produced liposomes in 1ml of liposome solution  
We can produce around 1,500,000 liposomes in each 1 ml of liposome solution by using the lipid 
film hydration technique. 
         
Figure 3-1: Transmission electron microscopy images of the liposomes prepared by the lipid film 
hydration technique. 
3.1.2 Diameters of liposomes produced by lipid film hydration  
The sizes of liposomes in a specific size of liposomes solution are measured by our group to 
figure out their size distribution. Results attained from these measurements indicate that the 
produced liposomes are 8-23 μm in their diameters and 56% of the liposomes’ own diameters are 
between 11-16 μm. Liposomes with this range of sizes are eligible to capture a sufficient number 
of MTB inside them since they are 4-11 times bigger than the MTB aimed to be encapsulated 
inside them. 
          
Figure 3-2: Transmission electron microscopy images showing the diameters of liposomes 
prepared by the lipid film hydration technique. 
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Table 3-1: Diameters of liposomes in 1ml of liposomes solution produced by lipid film hydration     
technique 
Sizes of liposomes Number of liposomes Percentage of liposomes of 
total number of liposomes 
8-10 μm 183977 20% 
11-13 μm 275966 30% 
14-16 μm 239171 26% 
17-19 μm 119585 13% 
20-23 μm 101187 11% 
  
3.2 Separation of non-encapsulated MTB by polycarbonate filters 
3.2.1 The separation efficacy of polycarbonate filters 
Polycarbonate filters are able to separate around 3.5×106 non-encapsulated MTB from the total 
amount of non-encapsulated MTB in liposomes solution (3.9×106 non-encapsulated MTB). 
These filters separate around 90.6% of the total percentage of non-encapsulated MTB while 
9.4% of non-encapsulated MTB are kept in the sample. 
 
Figure 3-3: Graph representing percentage of non-encapsulated MTB that have been separated 
from liposomes solution by polycarbonate filters. 
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A) The sample before separation of non-
encapsulated MTB. 
B) The sample after separation of non- 
encapsulated MTB.
Figure 3-4: Transmission electron microscopy images for the sample before and after the 
separation of non-encapsulated MTB by polycarbonate filters. 
3.2.2 Studying the influence of polycarbonate filters on the stability of liposomes 
The polycarbonate filters achieve segregation of a high percentage of non-encapsulated MTB 
reaching 90.63%, but we have to know their effect on the stability of liposomes. In general, 
the liposomes are still intact after the separation of the non-encapsulated MTB, but we observe 
that there is a decrease in the number of liposomes after the separation process is complete. 
Therefore, we count the number of liposomes before and after the separation of MTB. We find 
that 79.6% of liposomes are kept intact in the sample after the separation of non-encapsulated 
MTB by polycarbonate filters. 
 
Figure 3-5: Graph showing the percentage of intact liposomes after their separation by 
polycarbonate filters. 
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3.3 Release of liposomes 
3.3.1 Release of liposomes composed of DMPC by LFUS 
The low frequency ultrasound shows high performance in release of liposomes composed of 
DMPC since 95% of liposomes have been released by using low frequency ultrasound. 
 
Figure 3-6: Graph explains the percentage of released liposomes by LFUS. 
 
 
(A).The sample before separation of non-encapsulated  (B) The sample after separation of non-encapsulated 
         MTB.                                                                              MTB. 
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 (C) The sample before release of liposomes by LFUS     (D) The sample after release of  liposomes by  LFUS 
Figure 3-7: Transmission electron microscopy images representing the release of liposomes by 
LFUS. 
3.3.1.1 The encapsulation efficacy of liposomes prepared by the lipid film 
hydration technique. 
The results obtained by our group show that we can encapsulate around 857807 MTB in every 
1ml of liposome solution. 
3.3.1.2 The number of non-separated non-encapsulated MTB in every 1 ml of 
liposome solution. 
57550 non-separated non-encapsulated MTB stayed in every 1 ml of liposomes solution.  
 
Figure 3-8: Graph showing the number of non-encapsulated and encapsulated MTB in the 
sample after the separation process. 
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3.3.1.3 The percentage of MTB entrapped inside liposomes 
 
Figure 3-9: Graph manifesting the percentage of encapsulated MTB from the total number of 
MTB aimed to be encapsulated in the liposomes. 
3.3.2 Release of liposomes by the effect of body temperature (37°C) and body pH 
Both body temperature and body pH are unable to release liposomes composed of DMP by 
lipid film hydration technique during 30 minutes of exposure.   
  
Figure 3-10: Graph representing the effect of body temperature and body pH on the release of 
liposomes composed of DMPC. 
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          (A) The sample before the separation of non-             (B) The sample after the separation of non-                    
                 encapsulated  MTB.                                                    encapsulated MTB.
 
          
          (C) The sample 5 minutes after exposure                   (D) The sample 15 minutes after exposure to                                   
.                to 37 oC  and   body pH .                                             37 oC and body pH. 
 
               
        (E) The sample 20 minutes after exposure               
.               to 37 °C and body pH.     
(F) The sample 30 minutes after exposure to                             
.      37 °C and body pH. 
Figure 3-11: The transmission electron microscopy images showing the effect of body 
temperature and body pH on the release of liposomes composed of DMPC. 
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3.4 The effect of body temperature on the liveability rates of MTB 
Around 96.53% of MTB have survived during first 15 minutes of their exposure to 
human body temperature whereas 92.6% of them survived after their exposure to 37oC 
for 20 minutes. The sharp decrease in the percentage of alive MTB after exposure to 
human body temperature has appeared after 25 and 30 minutes where 55.6 % and 17.3% 
of MTB have survived respectively.  
Figure 3-12: Graph representing the percentage of living MTB after exposure to body 
temperature for different time intervals. 
 
 
 
 
34 
 
CHAPTER 4    DISCUSSION 
4.1 Encapsulation of MTB inside liposomes  
The lipid film hydration technique shows high reproducibility of liposomes that are big 
enough to encapsulate big particles such as MTB inside them. This technique produces 
more than one million liposome in every 1ml of liposomes solution. Liposomes 
produced by this technique are between 8-23 μm in their diameters and 56% of them 
have diameters between 11-16 μm. According to our results, liposomes encapsulate 
14.1% of the targeted number of MTB. Although the produced liposomes manifest low 
encapsulation efficacy, 857807 MTB encapsulate inside each 1ml of liposomes solution 
with around 1 MTB entrapped inside each liposome. This high number of encapsulated 
MTB is able to carry sufficient quantities of anticancer medications since each MTB is 
able to carry particles with sizes around 150 nm. We could encapsulate the MTB inside 
liposomes using MTB in their media as a water phase instead of using water or PBS as a 
water phase as it is used in all of the liposomes production techniques. The successes in 
preparation of liposomes using MTB media as a water phase enables us to encapsulate 
the MTB inside liposomes with their media. Because the produced liposomes are 
opaque, we are unable to see inside them to investigate the encapsulation efficacy of 
liposomes produced by lipid film hydration. The investigation of encapsulation efficacy 
is achieved after the separation of non-encapsulated MTB and the release of liposomes.  
4.2 Separation of liposomes by polycarbonate filters 
Liposomes are very fragile particles because they are composed of two layers of 
phospholipids. Since they are susceptible to breaking, the separation techniques used for 
the separation of particles could puncture or break them easily. The gel chromatography 
technique is employed to separate the liposomes by many research groups. 
Unfortunately, it is impossible to use this technique for the separation of non-
encapsulated MTB because it cannot be used for segregating particles that are bigger 
than 300 nm. Another method utilized for separating particles is cellulose filters, but we 
lost our sample when we studied the isolation of the non-encapsulated MTB using 
cellulose filters. Liposomes precipitate and attach at the bottom of centrifuge tube when 
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we exploit the centrifugation technique to isolate the non-encapsulated MTB although 
we study the separation by centrifugation for different time intervals with different 
centrifugation powers. The polycarbonate filters of 5 μm pores show the best results 
regarding the separation of non-encapsulated MTB. These filters manifest a high 
separation performance since they segregate 90.63% of the non-encapsulated MTB. The 
9.37% of non-encapsulated MTB remain in the sample after the separation process 
because some MTB adhere to the liposomes since liposomes are composed of 
phospholipids. Moreover, there are millions of non-encapsulated MTB in the sample 
and achieving 100% isolation is very hard for these numbers. Polycarbonate filters keep 
the integrity of the most liposomes since 79.6% of the liposomes collected are intact at 
the top of the polycarbonate filters. 20.4% of the liposomes are lost during the isolation 
process for the non-encapsulated MTB. Either they are broken during the separation 
process or they escape from the corners of the polycarbonate filters during the isolation 
process. Polycarbonate filters are hydrophobic which makes them resistant to passing 
water through them. As a result, any solution will slowly pass through them. By adding 
PBS or water, we can compensate the solution passed through the filters and collect 
liposomes suspended in PBS or water. In contrast, when we study the efficacy of 
cellulose filters to separate the non-encapsulated MTB, the solution passes quickly 
through the filters and the liposomes are broken because these filters are hydrophilic. 
4.3 Release of liposomes composed of DMPC 
The efficacy of utilizing the LFUS to release liposomes is tested before the other 
techniques for release such as body temperature and body pH because it is a controlled 
method for liposomes release. The LFUS 3W/cm3  released 95% of liposomes during 3 
minutes of exposure. This technique achieves a great releasing performance as a 
controlled liposomes release technique. The results collected by our group are close to 
the results achieved by other groups that promote exploiting the LFUS for the controlled 
release of liposomes. Efficiency of releasing liposomes by the LFUS seems to be caused 
by the cavitation (formation bubbles in a liquid and collapsing them) that happens 
besides liposomes membranes or inside liposomes induced by LFUS. When cavitation 
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occurs, pores formed in liposomes membranes followed by their collapse leads to the 
release of their entrapped content.  
The body temperature and body pH are uncontrolled methods for the release of 
liposomes. We study the effects of body temperature and body pH on the release of 
liposomes composed of DMPC by suspending the liposomes in PBS of pH 7.4 and 
exposing them to 37°C for 30 minutes. The results attained from these experiments 
indicate that there is no significant increase in the number of MTB or significant 
decrease in the number of liposomes during the exposure to body temperature and body 
pH during the 30 minutes of their exposure. The cause of the stability of liposomes 
composed of DMPC at the body pH is attributed to the chemical characteristics of 
DMPC. DMPC is not recognized among pH-sensitive liposomes composing 
phospholipids such as 1, 2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and 
phosphatidylethanolamine (PE) that could release their contents as a response to 
changes in the pH in the environment that surrounds them. As a result, liposomes 
composed of DMPC resist releasing their contents under the influence of body pH. 
Liposomes prepared from DMPC are temperature sensitive liposomes because their 
transition temperature is lower than the body temperature. Since liposomes prepared 
from DMPC are thermosensitive, they have to release their contents when the 
temperature is elevated more than their transition temperature. When the temperature is 
elevated more than the transition temperature of phospholipids that composes 
liposomes, the lipid bilayer of liposomes starts to lack its ordering and becomes 
disorganized. With continuous exposure to body temperature, the fluidity of the lipid 
bilayer increases and the liposomes start to release their contents. Liposomes composed 
of DMPC do not manifest a significant release of their entrapped MTB during 30 
minutes of exposure to the body. MTB is too large to go through the small pores formed 
in the membrane of the liposomes as a result of exposure to body temperature. MTB are 
2 µm in size and the liposomes’ own sizes are between 8-23 µm. Therefore, pores larger 
than 2 µm have to be composed in the lipid bilayer of liposomes or the liposomes have 
to collapse, so the MTB can escape from them.  
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4.4 Effect of body temperature on liveability of MTB  
Generally, MTB prefer to live and grow at room temperature, but the human body 
temperature is 13-14°C higher than the temperature preferred for growth of MTB. 
Therefore, we study the surviving ability of MTB at body temperature to determine the 
availability of navigation the MTB inside the human body as nano-robotics while 
keeping them alive. According to our results, 92.6% of MTB stay alive during the first 
20 minutes of exposure to the body temperature. This indicates that we can manipulate 
the MTB as nano-robotics inside the human body for 20 minutes without losing them. 
The percentage of alive MTB have dropped to 55.6 % after 25 minutes of exposure to 
37°C. This decrease in number of alive MTB indicates that the MTB are able to survive 
just for 20 minutes at body temperature and after that they will start to loss their 
activities and die. The sharp decrease in number of alive MTB has appeared after 30 
minutes of exposure to the body temperature where 17.3% of MTB survive after 
exposure to body temperature.  
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CONCLUSION AND RECOMMENDATIONS 
We study the characteristics of liposomes composed of DMPC by lipid film hydration 
technique. To achieve our goal we design a protocol composed of 3 steps. In the first 
step, we use the lipid film hydration technique to prepare liposomes composed of 
DMPC that entrap MTB inside them. We succeeded with the preparation of liposomes 
with diameters between 8-23 μm. These liposomes encapsulated 14.1% of the total 
amount of MTB targeted to be encapsulated inside liposomes. Lipid film hydration 
technique produced liposomes that are able to entrap big particles with 2 µm in their 
diameters. In addition, this technique showed high reproducibility of liposomes. These 
characteristics make lipid film hydration technique superior to produce liposomes that 
could encapsulate big particles inside them. We  have succeed in obtaining liposomes  
by creation some modifications in the protocol of the preparation of liposomes through 
the lipid film hydration technique using MTB in their media as a hydration solution 
instead of utilizing water or a buffer saline as a hydration solution. Polycarbonate filters 
are manipulated to separate the non-encapsulated MTB in the second step. According to 
our knowledge, this is the first time we are able to manipulate polycarbonate filters to 
separate non- encapsulated particle. These filters are able to separate 90.63% of the non-
encapsulated MTB while keeping most of liposomes intact during the encapsulation 
procedure. During the third step, we assess the efficacy of LFUS as a controlled way to 
release liposomes composed of DMPC. 95% of liposomes are released by low 
frequency ultrasounds (3 W/ cm3) during 3 minutes of exposure to LFUS. According to 
our results, both body pH and body temperature did not show any efficiency in the 
release of liposomes composed of DMPC 30 minutes after their exposure to body 
temperature or body pH. 
After we succeed in encapsulation of MTB inside liposomes, we are able to navigate 
MTB through the blood vessels and we can protect the normal healthy tissues from 
anticancer medications that are attached to MTB by antibodies. The produced liposomes 
can be manipulated as vectors to deliver medications attached to MTB to tumor masses. 
The movement direction of these vectors inside the human body can be controlled by 
applying magnetic fields on magnetosomes of MTB encapsulated inside these carriers 
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while the location of these vectors inside the human body can be determined by MRI 
system. When liposomes reach tumor masses can be released by LFUS to release the 
entrapped medications. 
Future works that could be done to achieve the encapsulation of MTB in liposomes: 
1. Exploiting the lipid film hydration technique to entrap MTB in liposomes composed 
of phospholipids with a transition temperature lower than the DMPC transition 
temperature although the low stability of these liposomes will be an obstacle in 
achieving the goal successfully.  Cholesterol could be used to enhance the stability of 
theses liposomes. 
2. Manipulation of pH-sensitive phospholipids such as DOPE and PE instead of DMPC 
to prepare liposomes although their lower transition temperature could cause the very 
quick release of liposomes after their injection in the human body. Adding cholesterol to 
them could increase their stability. 
Contributions 
1. According to our knowledge this is the first time that a researcher manipulate 
polycarbonate filters to separate the non-encapsulated particles from liposomes solution. 
This kind of filters can be utilized to separate the non-encapsulated MTB from 
liposomes solution and to separate liposomes from each other depending on their sizes 
since these filters are available with many pores sizes. 
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